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IMPROVE trial investigators, Powell JT, Hinchliffe RJ, et al. Brit J Surg
2014;101:216-24.
Conclusions: Outcomes for repair of ruptured abdominal aortic an-
eurysms (rAAA) might be improved by wider use of local anesthesia for
EVAR and by recognizing that a minimum blood pressure of 70 mmHg
may be too low a threshold for permissive hypotension.
Summary: Most data on outcomes of patients with rAAAs are single-
center studies and as such may be too small to identify clinical factors that
could improve overall patient outcomes. The IMPROVE study is a pragmatic
multicenter randomized clinical trial in which eligible patients with a clinical
diagnosis of rAAA were allocated to a strategy of endovascular repair of
RAAAA (EVAR) or to open repair. IMPROVE showed no difference in
30-day mortality with a strategy incorporating EVAR for repair of a rAAAA
compared to a strategy of open repair for ruptured abdominal aortic aneu-
rysm (IMPROVE trial investigators, Brit Med J 2014;348:f7661). In this
paper the IMPROVE investigators sought to analyze inﬂuences of time
and manner of hospital presentation, ﬂuid volume status, type of anesthesia,
type of endovascular repair and time to aneurysm repair on 30-day mortality
for rAAA. This was a prespeciﬁed plan of analyses to include only the patients
who underwent aneurysm repair for a proven diagnosis of rAAA . Adjust-
ments were made for potential confounding factors. In IMPROVE, 568 of
613 randomized patients had a symptomatic or rAAA and diagnostic accu-
racy was 91%. Patients randomized outside routine working hours had higher
operative mortality (adjusted odds ratio, 1.47, 95% CI, 1.00-2.17). There
was no difference in mortality rates between those patients admitted directly
to a trial center versus those transferred to a trail center from a referring insti-
tution. Lowest systolic blood pressure was strongly and independently asso-
ciated with 30-day mortality (51% among those with systolic blood pressures
below 70 mmHg). In addition, patients who received EVAR under local
anesthesia alone had reduced 30-day mortality compared to those who had
EVAR under general anesthesia (adjusted odds ratio, 0.27; 95% CI,
0.10-0.70). In patients with conﬁrmed rupture the time from randomization
to the operating suite was not associated with 30-day mortality (P ¼ .415).
Comment: The data indicate that blood pressure of 70 mmHg may
be too low for optimal results in a patient with rAAA and permissive hypo-
tensive levels should be above this. In addition, when EVAR is used to treat
a rAAAA it may be best to do it, if possible, under local anesthesia. Finally,
given the fact that results for repair of rAAA are no worse for a patient who
is transferred than for those with a primary presentation to a specialist cen-
ter, along with the fact that patients undergoing off-hours repair do more
poorly suggests that a skilled multidisciplinary vascular team including spe-
cialists anesthesia services is likely to provide the best results for repair of a
rAAA in any individual region. Outcomes for patients with rAAA therefore
may be best served by a policy of regionalization of care for such patients to
specialized centers.
Aneurysm Global Epidemiology Study: Public Health Measures Can
Further Reduce Abdominal Aortic Aneurysm Mortality
Sidloff D, Stather P, Dattani N, et al. Circulation 2014;129:747-53.
Conclusions: Abdominal aortic aneurysm (AAA) mortality has not
declined globally. Differences between nations in aneurysm mortality can
be explained by variations in traditional cardiovascular risk factors.
Summary: In the 20th century, abdominal aortic aneurysm (AAA)
was a disease with an increasing incidence and prevalence. As a result, there
were randomized trials of ultrasound AAA screening to access the beneﬁt of
screening in reducing AAA related mortality. In addition, recent data sug-
gests in Western populations there has been a decline in both AAA incidence
and mortality in the 21st century. A more global evaluation of aneurysm
mortality has not been performed and international trends are unclear.
The current study attempted to investigate global AAA mortality trends
and to analyze any association with common cardiovascular risk factors.
The World Health Organization (WHO) mortality database was age stan-
dardized and AAA mortality from 1994 to 2010 extracted, using Interna-
tional Classiﬁcation of Diseases codes (ICD 10). In addition the WHO
InfoBase and International Mortality and Smoking Statistics provided risk
factor data. 19 WHO member states that were included in the analysis
(14 from Europe, 2 Australasian countries, 2 North America countries,
and 1 Asian country). Regression analysis was performed with temporal
trends in cardiovascular risk factors (1946-2010) and was done indepen-
dently for correlation to AAA mortality trends. Global AAA mortality trends
showed substantial heterogeneity, with the United States and United
Kingdom demonstrating the greatest national declines. Internationally
male individuals and those <75 years of age demonstrated the greatest
reductions. However, in Hungary, Romania, Austria and Denmark AAA
related mortality increased indicating declines are not necessarily universal.There was a positive linear relationship between global trends in systolic
blood pressure (P # .03), cholesterol (P # .03), and smoking prevalence
(P # .02) in males and females. There was a negative linear association of
body mass index with AAA mortality (P # .007). There was no association
with fasting glucose levels.
Comment: The data indicated that declines in smoking prevalence
correlate most closely with declines in AAA mortality. This in combination
with the proven beneﬁt of AAA screening in reducing AAA mortality, sug-
gests that relatively well recognized public health measures and relatively
easily implemented public health measures to address smoking prevalence
and introduce AAA screening, are the keys to a further world-wide decline
in AAA related mortality.
Long-Term Coffee Consumption and Risk of Cardiovascular
Disease: A Systematic Review and a Dose-Response Meta-Analysis of
Prospective Cohort Studies
Ding M, Bhupathiraju SN, Satija A, et al. Circulation 2014;129:643-59.
Conclusions: There is a nonlinear association between coffee con-
sumption and cardiovascular disease (CVD) risk. Moderate coffee consump-
tion is associated inversely with CVD risk with the lowest CVD risk at 3 to 5
cups per day. Heavy coffee consumption is not associated with an elevated
CVD risk.
Summary: Coffee is one of the most widely consumed beverages in the
world. In the early 1960’s it was noted that therewas a high prevalence of both
coffee consumption and coronary heart disease in Western countries. In addi-
tion, short-term metabolic studies have found that caffeine ingestion induces
cardiac arrhythmias and increases plasma renin activity, and catecholamine
concentrations as well as blood pressure (Robertson D et al, NEJM
1978;298:181-6, and Dobmeyer DJ et al, NEJM 1983;308:814-6). In addi-
tion a 1980’s cross-sectional study showed a positive association between cof-
fee consumption and total serum cholesterol concentrations (Thelle DS et al,
Atherosclerosis 1987;67:97-103). A later randomized trial also showed that
boiled coffee consumption increased serum cholesterol (Bak AA et al,
NEJM 1989;321:1432-7). What followed was in the 1980’s and 2000’s a
number of case-controlled series reporting to examine coffee consumption
and relationship to CVD risk. Such series were prone to recall bias and selec-
tion bias, but demonstrated a positive association between coffee consump-
tion and coronary heart disease risk. However, later previous meta-analyses
of prospective cohort studies tended to ﬁnd no association between coffee
consumption and CVD risk but results varied substantially across studies
(Kawachi I et al, BrHeart J 1994;72:269-75, andGreenland S, Epidemiology
1993;4:366-74). There have been a number of additional studies since previ-
ousmeta-analyses. The current study was therefore designed to study a poten-
tial dose-response association of coffee consumption with CVD risk. This
study was conducted as a systematic review and meta-analyses of coffee con-
sumption and incidence of total CVD outcomes including incidence of coro-
nary heart disease, stroke, heart failure, and cardiovascular disease mortality.
PubMed and EMBASE were searched for prospective cohort studies of the
relationship between coffee consumption and CVD risk. CVD risk included
coronary heart disease, stroke, heart failure, and cardiovascular disease mortal-
ity. There were 36 studies identiﬁed as suitable for inclusion in the meta-ana-
lyses and they included 1,279,804 subjects and 36,352 CVD cases. A
nonlinear relationship of coffee consumption with CVD risk was identiﬁed
(P for heterogeneity ¼ .09, P for trend <.001, P for nonlinearity <.001).
Compared with the lowest category of coffee consumption (median, 0 cups
per day), the relative risk of CVD was 0.95 for the second highest category
(median, 3.5 cups per day). It was 0.89 (95% CI, 0.84-0.94) for the third
highest category (median, 1.5 cups per day). Looking at individual outcomes
coffee was not linearly associated with both coronary heart disease (P for het-
erogeneity ¼ .001, P for trend <.001, P for nonlinearity <.001) and stroke
(P for heterogeneity ¼ .07, P for trend <.001, P for nonlinearity <.001; P
for trend differences >.05).
Comment: The study demonstrates a nonlinear U-shaped relation-
ship between coffee consumption and CVD risk. This may be due to a com-
bination of beneﬁcial and detrimental effects of coffee consumption. It is
possible that for moderate coffee consumption beneﬁcial effects are greater
than adverse effects whereas with heavy consumption detrimental effects
overwhelm beneﬁcial effects. It must, however, be kept in mind that given
the observational nature of the studies analyzed residual confounding vari-
ables cannot be absolutely excluded. It may be that higher coffee consump-
tion is associated with a less healthy life style and a higher prevalence of
cigarette smoking, less physical activity, and a less healthy diet perhaps
explaining the U-shaped nature of the curve. Overall one can view the
data as suggesting that low or moderate coffee consumption is not associ-
ated with increased CVD risk. However, the nonlinear association of coffee
consumption with risk of both coronary heart disease and stroke may be
inﬂuenced by the association of unrecognized adverse confounders for
vascular disease associated with heavy coffee consumption.
